FB 811Alternative Names: FB811; Glycosylated rituximab - Fountain Biopharma; Rituximab biobetter - Fountain Biopharma
Latest Information Update: 04 Sep 2015
At a glance
- Originator Fountain BioPharma
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Non-Hodgkin's lymphoma
Most Recent Events
- 04 Sep 2015 Preclinical trials in Non-Hodgkin's lymphoma in Taiwan (IV) before September 2015